Under the terms of the agreements, deCODE will receive an upfront payment and royalties on sales of testing products incorporating its markers. Additional financial details were not disclosed.
"This is an excellent opportunity to broaden the clinical application and commercialization of our discoveries of high-impact genetic risk factors for major diseases. The markers included in these agreements are among the most widely replicated genetic risk factors for cardiovascular and metabolic disease, and they provide a natural complement to the biomarker services already offered by Berkeley HeartLab, Celera's subsidiary. In Celera we have a partner with a global reputation in human genetics and a large and effective outreach and sales force. We are pleased to have the chance to work with them to build upon our discovery and testing platforms and to accelerate the adoption of personalized medicine," said Kari Stefansson CEO of deCODE.
"We believe access to these highly replicated markers, which complement
our internal proprietary genetic discoveries in cardiovascular disease such
as KIF6 and LPA, furthers Celera's commitment to be a leading provider of
genetic tests used routinely in personalizing disease management," said Kathy
OrdoÃ±ez, CEO of Celera. "We expect Berkeley HeartLab to incorporate these
markers into future laboratory service offerings, and Celera plans to
ultimately commercialize them globally as new molecular diagnostic tests
through our Products business. We believe these markers that predict risk of
coronary heart disease and drug response could produce highly differentiated,
proprietary, and compelling tests that personalize
|SOURCE deCODE genetics Inc|
Copyright©2009 PR Newswire.
All rights reserved